Search clinical trials for: BGB-A445

Total 1301 results

University of Maryland, Baltimore
Maryland Industrial Partnerships; Telcare, Inc

Terminated

Smart Glucose Meter Project

Type 1 Diabetes | Type 2 Diabetes

United States
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Hidradenitis Suppurativa

China
BioAge Labs, Inc.

Withdrawn

Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery

Acute Posthemorrhagic Anemia

Australia
BeiGene

Recruiting

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Emory University
US Department of Veterans Affairs

Recruiting

Sympathetic Overactivity in Post-traumatic Stress Disorder (SO-PTSD)

Prehypertension | Post-traumatic Stress Disorder

United States
National University Hospital, Singapore

Completed

Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH)

Non Alcoholic Steatohepatitis

Singapore
BeiGene

Completed

A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma

B-cell Lymphoma

China
Peking University People's Hospital

Recruiting

Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma

CNS Lymphoma

China
BeiGene

Completed

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

B-cell Malignancies

United States, Korea, Republic of, Australia, New Zealand, United Kingdom, Italy
BeiGene

Completed

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Relapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma

China
BeiGene

Completed

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

Triple Negative Breast Cancer | Advanced High-grade Ovarian Cancer

China
BeiGene

Completed

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

Waldenström's Macroglobulinemia (WM)

China
InSightec

Completed

ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy

Glioblastoma Multiforme

Korea, Republic of
AstraZeneca
Parexel

Completed

A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol

Chronic Obstructive Pulmonary Disease (COPD)

United States
Gedeon Richter Plc.

Completed

Study to Compare the Pharmacokinetics and Pharmacodynamics of 6 mg RGB-02 to 6 mg Neulasta

Bioequivalence

United Kingdom
AstraZeneca
Parexel

Not yet recruiting

A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C)

Healthy

Germany
Geron Corporation

Completed

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

Multiple Myeloma

United States
BeiGene

Active, not recruiting

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

Mature B-cell Malignancies

Japan
BeiGene

Completed

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Refractory Mantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma

China
BeiGene

Completed

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Defengrui Biotechnology Co. Ltd

Terminated

Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS

COVID-19 Pneumonia

Spain, Bangladesh, China, India, Indonesia
St. Olavs Hospital
Rosenborgklinikken

Recruiting

Fixation of Patellar Tendon Grafts in Anterior Cruciate Ligament Reconstruction. Endobutton vs Metal Interference Screws

Knee Injuries

Norway
University of Chicago

Recruiting

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma | Head and Neck Cancer Stage IV | Head and Neck Cancers - Throat

United States
AstraZeneca

Recruiting

A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C).

Chronic Obstructive Pulmonary Disease

Germany, United Kingdom
BeiGene

Completed

BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma

Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma

China
Sciberras, Stephen M.D.
University of Malta

Recruiting

Non-Invasive Vital Signs Monitoring (NIVS) Project (NIVS)

Hemodynamic Monitoring | Monitoring, Physiologic

Malta
InSightec

Recruiting

ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

Alzheimer Disease

United States
Ohio State University
National Cancer Institute (NCI); University of North Carolina, Chapel Hill; University...

Completed

Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention

Intraepithelial Neoplasia | Squamous Cell Carcinoma of Mouth

United States
BeiGene

Completed

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Advanced or Inoperable Gastric Cancer

United States, Hungary, Spain, China, Hong Kong, Japan, Australia, Taiwan, Belgium, Czechia, Singapore, France, Poland, United Kingdom, Romania, Russian Federation, Georgia
BeiGene

Completed

Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants

COVID-19 | COVID-19 Pulmonary Complications

United States
BGI, China
Fudan University; Shanghai 10th People's Hospital

Recruiting

Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

Solid Tumor

China
BeiGene

Completed

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

B-cell Lymphoid Malignancies

Australia, Korea, Republic of, United States
BeiGene

No longer available

A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies

Waldenström Macroglobulinemia

United States
West China Hospital

Recruiting

Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma (neoCHANCE-1)

Head and Neck Cancer

China
BeiGene

Active, not recruiting

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors

Advanced Solid Tumor

China
InSightec
Focused Ultrasound Foundation

Recruiting

ExAblate Blood-Brain Barrier Opening for Treatment of Alzheimer's Disease

Alzheimer Disease

Canada
InSightec

Completed

Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma

Glioblastoma

Canada
Dr. Sabrina Overhagen
Bentley InnoMed GmbH

Active, not recruiting

BGP+ Stent as Bridging Stent in BEVAR

Thoracoabdominal Aortic Aneurysm, Without Mention of Rupture

Germany
Leslie Balcazar De Martinez

Completed

Evaluating the Feasibility of Using M-Health to Improve Serum Glucose Logs

Gestational Diabetes Mellitus

United States
William Black
Immunotec Inc.

Completed

DGB-01 Effects on Endurance Exercise

Fatigue

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

COPD

United States, Austria, Canada, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, Peru, Russian Federation, Hungary, China, Taiwan, Australia, Japan, Argentina, South Africa, Belgium, Czechia, Serbia, Poland, Mexico, New... and more
Yonsei University

Unknown

Assessment of Initial Efficacy and Safety of High Intensity Focused Ultrasound 'ExAblate 4000 Type 2' for Blood Brain Barrier Disruption in Patients With Alzheimer's Disease

Alzheimer Disease

Korea, Republic of
BeiGene

Completed

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) (ASPEN)

Waldenström's Macroglobulinemia

United States, Spain, Australia, France, United Kingdom, Germany, Netherlands, Czechia, Italy, Poland, Belgium, Greece, Sweden
BeiGene

Recruiting

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
CAGE Bio Inc.
John Peter Smith Hospital

Recruiting

An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection

Fungal Infection | Onychomycosis | Tinea Unguium

United States
University Hospital, Grenoble
Laboratoire de Psychologie et NeuroCognition; Laboratoire interuniversitaire...

Recruiting

Neurovegetative Decoupling in Somatoform Disorders : Biofeedback Interest (BIOFEESOMATO)

Irritable Bowel Syndrome | Somatoform Disorders | Psychogenic Non-Epileptic Seizure

France
BeiGene

Recruiting

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

Relapsed Diffuse Large B-cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

China
Tianjin Medical University Second Hospital

Recruiting

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study

High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

China
Tianjin Medical University Second Hospital

Recruiting

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Non-Muscle Invasive Bladder Urothelial Carcinoma | High-Risk

China
BeiGene

Recruiting

Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma

China

3

Subscribe